← Evidence map

ArticleCancer discovery2026

Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade.

Xing Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

4 papers cite it

2026

this papertrialcites it

Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade. | OpenQuestion